You are here

P&T News

May 31

Most regret the decision to change systems, survey finds
30-day readmission rate drops from 19% to 13%
Treatment may cause severe liver injury
Farnesoid X receptor agonist reduces alkaline phosphatase

May 27

Probuphine provides low-level buprenorphine for six months
First recombinant factor VIII single-chain therapy
Manufacturing issues sink ZS-9 application
Finding may herald emergence of pan–drug-resistant bugs

May 26

Class-action complaint alleges misrepresentation, false advertising
Publication outlines implementation strategies in acute care
Approval decision expected in July
If approved, drug would be first single-dose oral therapy for BV

May 25

Implanted rods offer controlled release of buprenorphine
Monoclonal antibody targets nerve growth factor
Advisors voted 7–3 against approval, but patient advocates clamor for a cure
Xaracoll is on schedule for 2017 launch

Pages